Upgrade to SI Premium - Free Trial

Stifel Reiterates Buy Rating on Intellia Therapeutics (NTLA)

November 7, 2024 10:43 AM
Stifel analyst Dae Gon Ha reiterated a Buy rating and $54.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles